

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

DARAPRIM
(pyrimethamine)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Treatment of Toxoplasmosis

Daraprim is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.

Compendial Uses

Toxoplasmosis; Prophylaxis^{2,3,4,5}

Pneumocystis jirovecii pneumonia; Prophylaxis^{2,3,4}

Cystoisosporiasis; Treatment and secondary prophylaxis^{2,4,5}

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of congenital toxoplasmosis in a pediatric patient

OR

- The requested drug is being prescribed for the treatment of toxoplasmosis

OR

- The requested drug is being prescribed for secondary prophylaxis of toxoplasmosis

AND

- The patient has had a CD4 cell count of less than 200 cells/mm³ within the past 6 months

OR

- The patient has experienced an intolerance or has a contraindication to sulfamethoxazole/trimethoprim AND the requested drug is being prescribed for any of the following: A) primary prophylaxis of toxoplasmosis, B) *Pneumocystis jirovecii* pneumonia prophylaxis

AND

- The patient has had a CD4 cell count less than 200 cells/mm³ within the past 3 months

OR

- The patient has experienced an intolerance or has a contraindication to sulfamethoxazole/trimethoprim AND the requested drug is being prescribed for the treatment of cystoisosporiasis

OR

- The patient has experienced an intolerance or has a contraindication to sulfamethoxazole/trimethoprim AND the requested drug is being prescribed for secondary prophylaxis of cystoisosporiasis

AND

- The patient has had a CD4 cell count less than 200 cells/mm³ within the past 6 months

REFERENCES

1. Daraprim [package insert]. New York, New York: Vyera Pharmaceuticals, LLC; August 2017.

2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2022; Accessed November 29, 2022.
3. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <https://www.micromedexsolutions.com/>. Accessed November 29, 2022.
4. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Available at <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection>. Accessed November 29, 2022.
5. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Available at <https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection>. Accessed November 29, 2022.
6. Treatment of Malaria: Guidelines for Clinicians (United States). Centers for Disease Control and Prevention. Available at https://www.cdc.gov/malaria/diagnosis_treatment/index.html. Accessed November 29, 2022.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv>. Accessed November 29, 2022.